Werewolf Explores Strategic Alternatives To Advance PREDATOR Platform And Oncology Pipeline

Werewolf Therapeutics, Inc. announced that it is exploring a full range of strategic alternatives aimed at advancing its proprietary platform and clinical pipeline while maximizing shareholder value. To support this process, the company has appointed Piper Sandler & Co. as its exclusive financial advisor.

The company stated that there is no set timeline for completing the evaluation and no assurance that the review will result in a transaction or other strategic outcome. Werewolf emphasized that it does not intend to provide updates on the process unless its board approves a specific action or determines that further disclosure is necessary.

“We have initiated a process to explore a range of alternatives available to the Company to maximize stockholder value. Such measures may include, among other options, a sale of the Company, a business combination or merger, a sale of assets, licensing or collaboration arrangements, or other strategic transactions,” said Dan Hicklin, PhD, President and CEO of Werewolf. “In addition to our clinical-stage candidates and our named earlier-stage candidates, our INDUKINE and INDUCER platforms provide exciting opportunities to apply our differentiated masking and protease linker technology in multiple additional modalities.”

Werewolf is focused on developing therapeutics engineered to activate the body’s immune system against cancer and other immune-mediated diseases. Its proprietary PREDATOR platform is designed to create conditionally activated INDUKINE and INDUCER molecules that stimulate both adaptive and innate immune responses while aiming to overcome limitations associated with traditional proinflammatory immune therapies.

The company’s most advanced clinical-stage candidates include WTX-124 and WTX-330, systemically delivered INDUKINE molecules based on Interleukin-2 (IL-2) and Interleukin-12 (IL-12), respectively. These therapies are engineered to remain inactive in peripheral tissues and selectively activate within the tumor microenvironment, targeting solid tumors with improved precision and safety.